TELCON RF PHARMACEUTICAL. Inc.

Total Valuation

TELCON RF PHARMACEUTICAL. Inc. carries a market capitalization of 19.45B, placing it among publicly traded companies globally. Its enterprise value stands at 50.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

TELCON RF PHARMACEUTICAL. Inc. currently has 6.85M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.95, and the price-to-book ratio stands at -0.30.

Enterprise Valuation

On an enterprise value basis, TELCON RF PHARMACEUTICAL. Inc. trades at an EV/EBITDA multiple of 63.08 and an EV/FCF ratio of 8.50. The EV/Sales ratio of 1.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 63.08 provides insight into valuation relative to core operating earnings.

Financial Position

TELCON RF PHARMACEUTICAL. Inc. maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.88, indicating elevated leverage, while an interest coverage ratio of 0.18 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

TELCON RF PHARMACEUTICAL. Inc.'s stock has declined approximately -85.27076% over the past 52 weeks. The 50-day moving average sits at 4,477.40, while the 200-day moving average is 8,148.30.

Income Statement

Over the trailing twelve months, TELCON RF PHARMACEUTICAL. Inc. generated 42.88B in revenue and converted that into -8.30B in net income, yielding earnings per share of -2,077.01. EBITDA reached 795.00M, while operating income came in at 795.00M.

Balance Sheet

TELCON RF PHARMACEUTICAL. Inc. holds 30.84B in cash and equivalents against 39.82B in total debt, resulting in a net debt position of 30.04B. Total book value stands at -134.86B, with working capital of 12.35B providing operational flexibility.

Cash Flow

TELCON RF PHARMACEUTICAL. Inc. produced 929.32M in operating cash flow over the past twelve months. After subtracting -524.63M in capital expenditures, free cash flow totaled 404.69M - equivalent to 81.72 per share.

Margins

TELCON RF PHARMACEUTICAL. Inc. operates with a gross margin of 24.55, reflecting its pricing power and cost economics. The operating margin of 1.85 and net profit margin of -19.35 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

TELCON RF PHARMACEUTICAL. Inc.'s most recent stock split took place on June 4, 2026 with a 10:1 split ratio.

Scores

TELCON RF PHARMACEUTICAL. Inc. posts an Altman Z-Score of -1.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.